Neurology

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

Congratulations Dr. Nikolaus McFarland on the publication of “Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial,” in the June edition of The Lancet Neurology.

Background

Progressive supranuclear palsy is a rare neurodegenerative disease associated with dysfunctional tau protein. BIIB092 is a humanised monoclonal antibody that binds to N-terminal tau and is thus being assessed as a potential novel treatment for progressive supranuclear palsy. We aimed to investigate the safety and tolerability of BIIB092 in individuals with progressive supranuclear palsy.

Source link




Related posts

Board games may stave off cognitive decline

Newsemia

Gocovri Treatment Effect Maintained for up to 2 Years in PD Patients With Dyskinesia

Newsemia

Is normal pressure hydrocephalus a risk factor for Alzheimer’s disease?

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy